Invesco Exchange-Traded Fund Trust - Invesco Biotechnology & Genome ETF Past Earnings Performance
Past criteria checks 0/6
Invesco Exchange-Traded Fund Trust - Invesco Biotechnology & Genome ETF's earnings have been declining at an average annual rate of -26.7%, while the Capital Markets industry saw earnings growing at 9.7% annually. Revenues have been growing at an average rate of 6.3% per year.
Key information
-26.7%
Earnings growth rate
-27.6%
EPS growth rate
| Capital Markets Industry Growth | 10.3% |
| Revenue growth rate | 6.3% |
| Return on equity | -18.3% |
| Net Margin | -3,496.6% |
| Last Earnings Update | 31 Oct 2023 |
Recent past performance updates
No updates
Recent updates
No updates
Revenue & Expenses BreakdownBeta
How Invesco Exchange-Traded Fund Trust - Invesco Biotechnology & Genome ETF makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Oct 23 | 1 | -39 | 1 | 0 |
| 31 Jul 23 | 1 | -7 | 1 | 0 |
| 30 Apr 23 | 1 | 24 | 1 | 0 |
| 31 Jan 23 | 1 | -11 | 1 | 0 |
| 31 Oct 22 | 1 | -46 | 1 | 0 |
| 31 Jul 22 | 1 | -60 | 1 | 0 |
| 30 Apr 22 | 1 | -75 | 2 | 0 |
| 31 Jan 22 | 1 | -3 | 2 | 0 |
| 31 Oct 21 | 1 | 69 | 2 | 0 |
| 31 Jul 21 | 1 | 78 | 2 | 0 |
| 30 Apr 21 | 1 | 86 | 1 | 0 |
| 31 Jan 21 | 1 | 55 | 1 | 0 |
| 31 Oct 20 | 1 | 24 | 1 | 0 |
| 31 Jul 20 | 1 | 13 | 1 | 0 |
| 30 Apr 20 | 1 | 2 | 1 | 0 |
| 31 Jan 20 | 1 | -1 | 1 | 0 |
| 31 Oct 19 | 1 | -4 | 1 | 0 |
| 31 Jul 19 | 1 | 5 | 1 | 0 |
| 30 Apr 19 | 1 | 14 | 2 | 0 |
| 31 Jan 19 | 1 | 16 | 1 | 0 |
| 31 Oct 18 | 1 | 18 | 1 | 0 |
| 31 Jul 18 | 1 | 22 | 1 | 0 |
| 30 Apr 18 | 1 | 26 | 1 | 0 |
| 31 Jan 18 | 2 | 40 | 1 | 0 |
| 31 Oct 17 | 3 | 54 | 1 | 0 |
| 31 Jul 17 | 3 | 38 | 1 | 0 |
| 30 Apr 17 | 3 | 22 | 1 | 0 |
| 31 Jan 17 | 4 | -37 | 2 | 0 |
| 31 Oct 16 | 4 | -96 | 2 | 0 |
| 31 Jul 16 | 5 | -104 | 2 | 0 |
| 30 Apr 16 | 7 | -112 | 2 | 0 |
| 31 Jan 16 | 7 | -56 | 3 | 0 |
| 31 Oct 15 | 7 | 0 | 3 | 0 |
| 31 Jul 15 | 6 | 59 | 3 | 0 |
| 30 Apr 15 | 6 | 118 | 2 | 0 |
| 31 Jan 15 | 5 | 117 | 2 | 0 |
| 31 Oct 14 | 5 | 117 | 2 | 0 |
| 31 Jul 14 | 3 | 92 | 2 | 0 |
| 30 Apr 14 | 2 | 67 | 2 | 0 |
| 31 Jan 14 | 1 | 70 | 1 | 0 |
| 31 Oct 13 | 1 | 73 | 1 | 0 |
| 31 Jul 13 | 1 | 53 | 1 | 0 |
Quality Earnings: PBE is currently unprofitable.
Growing Profit Margin: PBE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PBE is unprofitable, and losses have increased over the past 5 years at a rate of 26.7% per year.
Accelerating Growth: Unable to compare PBE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PBE is unprofitable, making it difficult to compare its past year earnings growth to the Capital Markets industry (3.3%).
Return on Equity
High ROE: PBE has a negative Return on Equity (-18.3%), as it is currently unprofitable.